14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SANA vs CRBU: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
SANA Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–1 Matrix Metrics)
SANA Overall Winner
6-Pillar Tally: SANA 3 – 2 CRBU (1 Tie)
Matrix Metrics: SANA 5 – 1 CRBU
As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) is the stronger overall head-to-head candidate over Caribou Biosciences, Inc. (CRBU) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SANA carries a Unified Composite Score of 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin), whereas CRBU carries 46.7/100 (HOLD) at $0.35 (N/M Forward P/E, -1140.6% operating margin).
Composite vs. Pillar Nuance: While CRBU currently prints a higher short-term Unified Composite Score (46.7/100 HOLD vs. SANA 44.3/100 HOLD), SANA captures the overall institutional head-to-head verdict (5–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1140.6% operating margin) and revenue trajectory (+0.0% vs. -26.9% YoY).
Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile CRBU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SANA vs CRBU. Trailing 12-month operating profitability (SANA 0.0% vs CRBU -1140.6%) and valuation multiples (SANA N/M vs CRBU N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $41.1M market capitalization and -1140.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SANA vs CRBU Key Questions & Quantitative Answers
As of Nov 16, 2026, Sana Biotechnology, Inc. (SANA) is the stronger overall head-to-head candidate over Caribou Biosciences, Inc. (CRBU) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SANA carries a Unified Composite Score of 44.3/100 (HOLD) at $1.88 (N/M Forward P/E, 0.0% operating margin), whereas CRBU carries 46.7/100 (HOLD) at $0.35 (N/M Forward P/E, -1140.6% operating margin). Composite vs. Pillar Nuance: While CRBU currently prints a higher short-term Unified Composite Score (46.7/100 HOLD vs. SANA 44.3/100 HOLD), SANA captures the overall institutional head-to-head verdict (5–1 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1140.6% operating margin) and revenue trajectory (+0.0% vs. -26.9% YoY). Technical & Structure Timing Caution: SANA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.6); meanwhile CRBU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 25.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SANA leads the Growth & Scale pillar: SANA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CRBU at -26.9% YoY revenue growth and +0.0% YoY earnings growth on $9.4M TTM revenue (N/A gross margin, -1140.6% operating margin). On trailing 12-month operating scale, SANA generates N/A in USD-normalized revenue versus $9.4M for CRBU. In operating R&D and SG&A reinvestment, SANA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRBU.
CRBU screens cheaper on headline valuation multiples. SANA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CRBU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SANA (-79.5% ROE) versus CRBU (-93.8% ROE) capital efficiency.
In options market volatility and institutional positioning, SANA carries 222.6% implied volatility (25th %ile, Balanced (25th–60th %ile)), a 0.61x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.82β · 78% Vol realized risk). By comparison, CRBU carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.53β · 94% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.